Skip to Content

Roche Holding AG ROG

Morningstar Rating
CHF 220.10 −1.40 (0.63%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Roche's Pharma Pipeline and Diagnostics Innovation Support a Wide Moat

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Price vs Fair Value

ROG is trading at a 42% discount.
Price
CHF 220.10
Fair Value
CHF 624.00
Uncertainty
Low
1-Star Price
CHF 377.68
5-Star Price
CHF 221.40
Economic Moat
Vbb
Capital Allocation
Fdjjcrzxj

Bulls Say, Bears Say

Bulls

Roche and its innovative U.S. arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ROG is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CHF 221.50
Day Range
CHF 218.70222.20
52-Week Range
CHF 217.00293.55
Bid/Ask
CHF 0.00 / CHF 0.00
Market Cap
CHF 175.47 Bil
Volume/Avg
1.1 Mil / 1.5 Mil

Key Statistics

Price/Earnings (Normalized)
11.24
Price/Sales
2.93
Dividend Yield (Trailing)
4.36%
Dividend Yield (Forward)
4.36%
Total Yield
4.36%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
103,605

Competitors

Valuation

Metric
ROG
ABBV
MRK
Price/Earnings (Normalized)
11.2414.6383.37
Price/Book Value
5.9927.718.42
Price/Sales
2.935.315.30
Price/Cash Flow
10.7714.3920.94
Price/Earnings
ROG
ABBV
MRK

Financial Strength

Metric
ROG
ABBV
MRK
Quick Ratio
0.990.630.68
Current Ratio
1.350.871.25
Interest Coverage
14.933.572.33
Quick Ratio
ROG
ABBV
MRK

Profitability

Metric
ROG
ABBV
MRK
Return on Assets (Normalized)
17.03%14.54%3.59%
Return on Equity (Normalized)
53.42%150.11%9.12%
Return on Invested Capital (Normalized)
26.30%28.30%5.88%
Return on Assets
ROG
ABBV
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoKthhmlwrmMrhsv$713.8 Bil
JNJ
Johnson & JohnsonWxltqskxPbxk$348.1 Bil
MRK
Merck & Co IncQnbwfrcqBjdl$317.6 Bil
ABBV
AbbVie IncNtnrphmxhCbvh$290.8 Bil
AZN
AstraZeneca PLC ADRRrcsnvzmyDkj$209.9 Bil
RHHBY
Roche Holding AG ADRHhkkyywyTvbjb$194.3 Bil
NVS
Novartis AG ADRKddrpnlcqYqkk$190.0 Bil
PFE
Pfizer IncBrvpqyyjDynt$143.9 Bil
AMGN
Amgen IncFkbznqkqpJnjg$141.5 Bil
SNY
Sanofi SA ADRXsjzxvxkKfmqj$115.1 Bil

Sponsor Center